Jeremy Clark is Senior Research Associate in the Norwich Medical School at UEA. His research is in the diagnosis of, and the prediction of treatments for, prostate cancer. He is working on a urine-based test for prostate cancer to make detection easier compared with the commonly-used and more invasive or less reliable methods through, for example, biopsies and MRI scanning. His work – involving a multi-university team from seven countries - has been funded by the Movember Europe charity.
Areas of Expertise (5)
Treatments for Prostate Cancer
Urine-Based Test for Prostate Cancer
Media Appearances (5)
Home urine test for prostate cancer
The Star Online online
Lead researcher Dr Jeremy Clark, from UEA’s Norwich Medical School, said: “Prostate cancer is the most common cancer in men in Britain. It usually develops slowly and the majority of cancers will not require treatment in a man’s lifetime. However, doctors struggle to predict which tumours will become aggressive, making it hard to decide on treatment for many men.
Prostate cancer: Home urine test could 'revolutionize diagnosis'
Medical News Today online
As lead researcher Dr. Jeremy Clark explains, “Because the prostate is constantly secreting, the collection of urine from men’s first urination of the day means that the biomarker levels from the prostate are much higher and more consistent.”
Prostate Cancer Screening: You Can Detect The Disease Through A Home Urine Test
International Business Times online
As per the researchers, led by Dr. Jeremy Clark, "The PUR test looks at gene expression in urine samples and provides vital information about whether a cancer is aggressive or 'low risk.”
This Urine Test For Prostate Cancer Is Designed To Be Used At Home
“Being able to simply provide a urine sample at home and post a sample off for analysis could really revolutionise diagnosis,” said lead researcher Dr Jeremy Clark, from UEA’s Norwich Medical School.
Home urine test could revolutionise prostate cancer diagnosis
Sky News online
Lead researcher Dr Jeremy Clark, from UEA's Norwich Medical School, said: "The PUR test looks at gene expression in urine samples and provides vital information about whether a cancer is aggressive or 'low risk'.
Development of a multivariable risk model integrating urinary cell DNA methylation and cell‐free RNA data for the detection of significant prostate cancerThe Prostate
2020 Prostate cancer exhibits severe clinical heterogeneity and there is a critical need for clinically implementable tools able to precisely and noninvasively identify patients that can either be safely removed from treatment pathways or those requiring further follow up.
A novel stratification framework for predicting outcome in patients with prostate cancerBritish Journal of Cancer
2020 Unsupervised learning methods, such as Hierarchical Cluster Analysis, are commonly used for the analysis of genomic platform data. Unfortunately, such approaches ignore the well-documented heterogeneous composition of prostate cancer samples. Our aim is to use more sophisticated analytical approaches to deconvolute the structure of prostate cancer transcriptome data, providing novel clinically actionable information for this disease.
A four‐group urine risk classifier for predicting outcomes in patients with prostate cancerBJU International
2019 To develop a risk classifier using urine‐derived extracellular vesicle (EV)‐RNA capable of providing diagnostic information on disease status prior to biopsy, and prognostic information for men on active surveillance (AS).
epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate CancerJCO Precision Oncology
2019 Liquid biopsies that noninvasively detect molecular correlates of aggressive prostate cancer (PCa) could be used to triage patients, reducing the burdens of unnecessary invasive prostate biopsy and enabling early detection of high-risk disease.
Methodology for the at-home collection of urine samples for prostate cancer detectionBiotechniques
2019 Urine from patients with prostate cancer (PCa) contains gene transcripts that have been used for PCa diagnosis and prognosis. Historically, patient urine samples have been collected after a digital rectal examination of the prostate, which was thought necessary to boost the levels of prostatic secretions in the urine.